Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spiroindolone KAE609 for falciparum and vivax malaria.
White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, Jeeyapant A, Jain JP, Lefèvre G, Li R, Magnusson B, Diagana TT, Leong FJ. White NJ, et al. Among authors: lefevre g. N Engl J Med. 2014 Jul 31;371(5):403-10. doi: 10.1056/NEJMoa1315860. N Engl J Med. 2014. PMID: 25075833 Free PMC article. Clinical Trial.
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ, Li R, Jain JP, Lefèvre G, Magnusson B, Diagana TT, Pertel P. Leong FJ, et al. Among authors: lefevre g. Antimicrob Agents Chemother. 2014 Oct;58(10):6209-14. doi: 10.1128/AAC.03393-14. Epub 2014 Aug 11. Antimicrob Agents Chemother. 2014. PMID: 25114127 Free PMC article. Clinical Trial.
Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.
Stein DS, Jain JP, Kangas M, Lefèvre G, Machineni S, Griffin P, Lickliter J. Stein DS, et al. Among authors: lefevre g. Antimicrob Agents Chemother. 2015;59(6):3493-500. doi: 10.1128/AAC.00340-15. Epub 2015 Apr 6. Antimicrob Agents Chemother. 2015. PMID: 25845867 Free PMC article. Clinical Trial.
Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).
Tiono AB, Tinto H, Alao MJ, Meremikwu M, Tshefu A, Ogutu B, Ouedraogo A, Lingani M, Cousin M, Lefèvre G, Jain JP, Duparc S, Hamed K. Tiono AB, et al. Among authors: lefevre g. Malar J. 2015 Apr 15;14:157. doi: 10.1186/s12936-015-0682-7. Malar J. 2015. PMID: 25886021 Free PMC article. Clinical Trial.
Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J. Kloprogge F, et al. Among authors: lefevre g. PLoS Med. 2018 Jun 12;15(6):e1002579. doi: 10.1371/journal.pmed.1002579. eCollection 2018 Jun. PLoS Med. 2018. PMID: 29894518 Free PMC article.
Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.
Djimdé AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, Lefèvre G, Borrmann S; B2303 Study Group. Djimdé AA, et al. Among authors: lefevre g. Antimicrob Agents Chemother. 2011 Sep;55(9):3994-9. doi: 10.1128/AAC.01115-10. Epub 2011 Jun 13. Antimicrob Agents Chemother. 2011. PMID: 21670177 Free PMC article. Clinical Trial.
509 results